Commercial Senju launches first-in-class dry eye disease drug in Japan PharmaphorumSenju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.CommercialOphthalmologyRead full story pharminent April 10, 2026 (Last updated: April 10, 2026) Pharmaphorum Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market. CommercialOphthalmologyRead full story Post navigation Previous: GSK again pulls application for leucovorin, touted by FDA as potential autism treatmentNext: With oral obesity race underway, all eyes are on Lilly’s Foundayo launch Related Stories Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026 Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026